Clinical Trials Logo

NSCLC, Stage IIIA clinical trials

View clinical trials related to NSCLC, Stage IIIA.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03736993 Completed - NSCLC, Stage IIIA Clinical Trials

Metabolomics Predict Therapy Response

PROLUNG
Start date: May 28, 2018
Phase: N/A
Study type: Interventional

Complete resection is the mainstay of treatment for stage I-IIIA resectable non-small cell lung cancer (NSCLC). However rates of recurrence of disease are high, with five-year survival rates ranging between 73% (stage IA) and 24% (stage IIIA). Therefore, a prognostic biological marker that stratifies between NSCLC patients whom surgery cures versus patients in whom surgery would be futile due to early disease relapse after surgery is eagerly awaited. The primary objective of this prospective study is to establish a prognostic marker of early disease progression after complete surgical resection in patients with stages I to IIIA NSCLC. For this purpose the investigator will compare the metabolic profile with disease progression or death within one year after complete surgical resection to the patients with a progression free survival. Furthermore the investigator will evaluate the changes in the metabolic profile after surgery and if changes in this metabolic profile over time can predict disease recurrence before it becomes clinically apparent.